Related Experiment Video

Updated: Oct 19, 2025

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.7K

miRNAs and androgen deprivation therapy for prostate cancer

Maria Yu Konoshenko1, Olga E Bryzgunova1, Pavel P Laktionov1

  • 1Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk 630090, Russia.

Biochimica Et Biophysica Acta. Reviews on Cancer
|September 17, 2021
PubMed

Insights

Identifying specific microRNAs (miRNAs) and genes can predict response to androgen deprivation therapy (ADT) in prostate cancer (PCa). These biomarkers may help personalize treatment for castration-resistant prostate cancer (CRPC) and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Androgen deprivation therapy (ADT) is a primary treatment for advanced prostate cancer (PCa).
  • Progression to castration-resistant prostate cancer (CRPC) leads to poor prognosis, necessitating reliable biomarkers for treatment adjustment.
  • MicroRNAs (miRNAs) are implicated in ADT response and CRPC development, suggesting their potential as predictive biomarkers.

Purpose of the Study:

  • To summarize and analyze available data on miRNAs associated with ADT response (resistance and sensitivity) in prostate cancer.
  • To identify and validate promising miRNA and gene biomarkers for predicting ADT response and CRPC development.
  • To investigate the molecular mechanisms underlying ADT resistance and CRPC, including key signaling pathways.

Main Methods:

  • Comprehensive literature review and analysis of existing data on miRNAs and ADT response.
  • Bioinformatic analyses to identify miRNA molecular targets and their reciprocal interactions.
  • Investigation of key pathways (testosterone, PI3K-AKT, VEGF) and associated genes in CRPC development.
  • Meta-analysis to select the most promising miRNA and gene markers.

Main Results:

  • Several miRNAs are associated with ADT response and CRPC development.
  • A meta-analysis identified 5 specific miRNAs (miR-125b, miR-21, miR-23b, miR-27b, miR-221) and 14 genes as promising predictors of ADT response.
  • These selected miRNAs and genes are involved in critical processes regulating CRPC progression.

Conclusions:

  • The identified 5 miRNAs and 14 genes show significant potential as predictive biomarkers for ADT response in prostate cancer.
  • These biomarkers could facilitate personalized therapy adjustments for patients with advanced PCa.
  • The findings support the potential utility of these markers in combination therapy strategies for advanced prostate cancer.
Keywords:
ADTAndrogen deprivation therapyCastration-resistant prostate cancerProstate cancerTherapy effectivenessmiRNA markers

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K